Three very different things travel under the word innovation in animal vaccination. Products you can order this week. Products licensed in one species and one country and nowhere else. And laboratory work that will not reach a farm for years, if it ever does. Conference slides tend to blur the three. A purchasing decision cannot afford to.
Key takeaways
- Recombinant HVT vector vaccines are the deployed innovation, with more than a dozen commercial products carrying Newcastle disease, infectious bursal disease, laryngotracheitis or avian influenza antigens.
- The RNA vaccine in commercial veterinary use is a self-replicating RNA particle platform, licensed since 2018 in swine, not the lipid nanoparticle format used in human medicine.
- Preventive avian influenza vaccination of ducks in France is the largest field test of a new vaccination policy in Europe, with an estimated 96% to 99% reduction in epizootic size in 2023 to 2024.
- The unsolved constraint is logistical. Cell-associated vaccines still travel in liquid nitrogen, and no amount of platform innovation removes that.
Vector vaccines are the innovation that already happened
The recombinant herpesvirus of turkeys vector is the workhorse of modern poultry vaccination. The principle is simple: take an HVT backbone that already establishes a lifelong, low-grade infection in the bird, insert the gene coding for a protective antigen from another pathogen, and you get protection against two diseases from one administration.
This is not emerging technology. More than a dozen HVT-based products have reached the market, among them VAXXITEK HVT + IBD and VAXXITEK HVT + IBD + ILT, Newxxitek HVT + ND, VECTORMUNE HVT ND and VECTORMUNE AI from Ceva, Innovax ND-ILT and Procerta HVT-ND. The direction of development is multivalency. Published work on multivalent vectored HVT vaccines reports full clinical protection against Newcastle disease and infectious bursal disease challenge alongside protection against highly pathogenic avian influenza, from constructs designed to control several diseases at once.
The research frontier here is construction speed. CRISPR/Cas9 editing is being used to insert expression cassettes into recombinant HVT genomes, which shortens the path from an emerging field strain to a candidate construct. That part is still laboratory work.
RNA vaccines in animal health exist, but not where most people assume
The RNA question comes up in every discussion of vaccine innovation, usually framed by human medicine. The veterinary reality is more specific. Merck Animal Health’s SEQUIVITY platform, which has held USDA licensure since 2018, produces custom prescription vaccines using RNA particle technology, that is self-replicating replicon particles rather than the lipid nanoparticle formulation used in human COVID-19 vaccines. Related, not identical.
Its licensed applications sit in swine: influenza A virus in swine, porcine circovirus, rotavirus and others. A neuraminidase-only swine influenza product was licensed in 2022, with an adjuvanted version for gilts and sows added in 2024. As of now this remains the only self-replicating RNA vaccine licensed for animals, and none of the commonly used USDA-licensed cattle vaccines uses mRNA technology. Anyone offering an mRNA poultry vaccine today is describing a research program, not a product.
| Technology | Status | What it means for a production site |
|---|---|---|
| Recombinant HVT vectors, multivalent | Licensed, in routine use | Fewer administrations for the same disease coverage |
| Self-replicating RNA particles | Licensed in swine, USA | Custom antigen selection against local strains, by prescription |
| Field avian influenza vaccination with DIVA | Deployed under national programs | Regulated participation, mandatory surveillance obligations |
| CRISPR-built vector constructs | Research | Nothing yet, watch the licensing pipeline |
| mRNA lipid nanoparticle vaccines in ruminants and poultry | Experimental | Nothing to purchase |
The largest live test running in Europe is a policy, not a molecule
The most consequential recent change in poultry vaccination is not a new platform but the decision to vaccinate in the field against highly pathogenic avian influenza. Since October 2023, France has vaccinated domestic ducks in production, initially with Volvac B.E.S.T. AI+ND administered at 10 and 28 days, plus a third dose at 56 days in high-risk zones and over winter, with RESPONS AI H5 added in May 2024. An updated national plan for the 2025 to 2026 campaign was issued in September 2025.
The published assessment of the first season is striking. Modelling work estimated that 314 to 756 outbreaks were averted in 2023 to 2024, a 96% to 99% reduction in the size of the epizootic attributable to vaccination. The same body of work is candid about the limits: combining the model with field vaccination data indicated that at any given moment, at most 40% to 50% of duck batches were fully protected, with a further 30% to 40% only partially protected.
Two lessons carry beyond France. Vaccination against avian influenza only exists as a package with surveillance, since trade partners need evidence that vaccinated flocks are not silently infected. The chosen vaccines allow a DIVA approach, differentiating infected from vaccinated animals, and evaluation found weekly sampling and testing of dead birds to be the most sensitive and timely surveillance strategy, at around 90% sensitivity. And a national campaign is judged on coverage achieved over time, not on the efficacy figure in the vaccine dossier.
The constraint nobody has innovated away
For all the platform work, the physical logistics have barely moved. Cell-associated Marek’s and vectored HVT vaccines are living infected cells, shipped in sealed glass ampoules and stored in liquid nitrogen at cryogenic temperature. They are fragile, they lose titer when handling deviates from a narrow protocol, and they leave no visible trace when they do.
That is why thermostability and formulation deserve more attention than they get in the innovation conversation. A vaccine that tolerates a wider handling window would change more outcomes on more sites than another antigen combination. Handling technique at the point of administration follows the same logic, which we look at from the animal’s side in our piece on welfare during vaccination.
Four questions to put to any innovation claim
- Licensed where, in which species? A marketing authorization is jurisdiction-specific and species-specific. Both need naming before anything else is discussed.
- Which challenge model produced the efficacy figure? Protection against a homologous laboratory challenge and protection under field pressure are different claims.
- What does it change in the handling chain? Storage temperature, reconstitution window and route of administration decide whether your site can actually run it.
- What surveillance or reporting comes attached? As avian influenza vaccination shows, the obligations around a product can weigh more than the product.
New platforms, older obligations
Whatever the technology, the record of what was administered to which batch is what an audit and a trade partner will ask for.
Sources: peer-reviewed literature on recombinant HVT vector vaccines and multivalent constructs; Merck Animal Health product information on the SEQUIVITY RNA particle platform and its USDA licensures; French Ministry of Agriculture avian influenza vaccination plans and published modelling of the 2023 to 2024 campaign, including work in Emerging Infectious Diseases; research on surveillance strategies in vaccinated duck flocks; published work on handling and storage of cell-associated Marek’s disease vaccines. Consulted August 2026.
Product names are cited to describe the state of the market. Which vaccine is appropriate for a given flock, and under which national program, is a veterinary and regulatory decision outside the scope of this article.